Skip to content
ChickenStockChickenStock
ResearchIMVT
Immunovant logo

Immunovant (IMVT) stock

NASDAQ

$34.19-2.45%(-0.86)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-13.93x

Net loss — not comparable

P/B

10.77x

P/S

—

Latest earnings

SEC filings

Jul–Sep 2026(FY2027 Q2)

Net income increased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

19 SEC filings
  • Pande AtulDirector · Nov 11, 2026Open-market sale3,000 shares · $108K
    Avg. price $36116,731 shares held after
  • Pande AtulDirector · Nov 11, 2026Option exercise3,000 shares · $25K
    Avg. price $8.43119,731 shares held after
  • Girao TiagoChief Financial Officer · Oct 28, 2026Open-market sale6,606 shares · $188K
    Avg. price $28.5234,192 shares held after
  • Stout Jay SChief Technology Officer · Oct 21, 2026Open-market sale2,595 shares · $75K
    Avg. price $28.94198,937 shares held after
  • Gloria MelanieChief Operating Officer · Oct 7, 2026Open-market sale2,241 shares · $72K
    Avg. price $32.06217,060 shares held after
  • Stout Jay SChief Technology Officer · Oct 7, 2026Open-market sale3,809 shares · $122K
    Avg. price $32.06
    Show 2 price lots
    • 2,213 shares × $32.06$71K
    • 1,596 shares × $32.06$51K
  • Van Tuyl ChristopherChief Legal Officer · Oct 7, 2026Open-market sale1,327 shares · $43K
    Avg. price $32.06175,218 shares held after
  • Venker EricChief Executive Officer · Oct 2, 2026Open-market sale3,506 shares · $120K
    Avg. price $34.11257,075 shares held after
  • Venker EricChief Executive Officer · Oct 1, 2026Disposition to the issuer85,886 shares · $2.9M
    Avg. price $33.65260,581 shares held after
  • Venker EricChief Executive Officer · Oct 1, 2026Option exercise92,187 shares · $1.3M
    Avg. price $14.46346,467 shares held after
  • Van Tuyl ChristopherChief Legal Officer · Sep 23, 2026Open-market sale2,846 shares · $103K
    Avg. price $36.36176,545 shares held after
  • Pande AtulDirector · Aug 28, 2026Open-market sale1,500 shares · $65K
    Avg. price $43.27116,731 shares held after
  • Pande AtulDirector · Aug 28, 2026Option exercise1,500 shares · $13K
    Avg. price $8.43118,231 shares held after
  • Gloria MelanieChief Operating Officer · Aug 20, 2026Open-market sale3,056 shares · $135K
    Avg. price $44.16219,301 shares held after
  • Pande AtulDirector · Jul 24, 2026Open-market sale1,500 shares · $60K
    Avg. price $39.8116,731 shares held after
  • Pande AtulDirector · Jul 24, 2026Option exercise1,500 shares · $13K
    Avg. price $8.43118,231 shares held after
  • Girao TiagoChief Financial Officer · Jul 23, 2026Open-market sale6,798 shares · $263K
    Avg. price $38.69240,798 shares held after
  • Stout Jay SChief Technology Officer · Jul 23, 2026Open-market sale2,857 shares · $111K
    Avg. price $38.69205,341 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Immunovant (IMVT) stock information

NASDAQ

Immunovant (IMVT) is listed on NASDAQ. Its market capitalization is about $7.1B. On trailing-twelve-month earnings the P/E ratio is -13.93, and the P/B ratio is 10.77. Return on equity is -77.3%. These figures are computed in-house from official filings and are reference information only.

Immunovant — frequently asked questions

What is the P/E ratio of Immunovant (IMVT)?
On a trailing-twelve-month basis, IMVT trades at a P/E ratio of -13.93. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Immunovant?
IMVT has a market capitalization of about $7.1B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.